Clinical trials: Prostatic Neoplasms, completed
Prostate Cancer
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
The goal of this clinical research study is to learn the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer.
- Trial name
- NCT00631527
- Testing
- Leuprolide, Goserelin, Sunitinib Malate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer
Study to Evaluate CCS1477 in Advanced Tumours
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT03568656
- Testing
- CCS1477, Abiraterone acetate, Enzalutamide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 219 people
- Sponsor
- CellCentric Ltd.
Metastatic Castration Resistant Prostate Cancer
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT03774056
- Testing
- HC-1119
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostate Cancer
Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery
For primary surgical treatment of prostate cancer the investigators compare the classic open surgery (radical retropubic prostatectomy, RRP) versus robot-assisted laparoscopic surgery (RALP).
- Trial name
- NCT01578356
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Recurrent Prostate Cancer
MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy
In this study we will test a new procedure to guide needle biopsies into the prostate gland based on MRI. This study will be conducted in patients who may have recurrence of their cancer in the prostate gland after radiation…
- Trial name
- NCT00775866
- Testing
- MRI-Guided Biopsy
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of…
- Trial name
- COBRA (NCT05249127)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Cancer, Gastrointestinal Cancer
Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study
This study examines the effect of a five-year multifactorial lifestyle intervention in the Oslo diet and antismoking study on long-term cancer risk.
- Conditions
- Cancer, Gastrointestinal Cancer, Lung Cancer, Urinary Tract Cancer
- Trial name
- NCT03410641
- Testing
- Diet and antismoking advice
- Volunteers
- 1,216 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Prostate Cancer
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Calcitriol may cause prostate cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as mitoxantrone and prednisone, work in different ways to stop the growth…
- Trial name
- NCT00182741
- Testing
- calcitriol, mitoxantrone hydrochloride, prednisone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer…
- Trial name
- NCT01834651
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Edwin Posadas, MD
Prostate Cancer
Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions
68Ga-PSMA is a radiopharmaceutical used with PET imaging for the detection of prostate cancer under a compassionate IND in patients who have presented with biochemical failure.
- Trial name
- NCT03213951
- Testing
- Experimental beta probe, PSMA-PET
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Indiana University
Metastatic Cancer, Pain
Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
RATIONALE: Ibandronate may be effective in reducing bone pain caused by metastatic cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Metastatic Cancer, Pain, Prostate Cancer
- Trial name
- NCT00082927
- Testing
- ibandronate sodium
- Where
- 52 sites in United Kingdom
- Volunteers
- 580 people
- Sponsor
- Cancer Research UK
Prostate Cancer, Neoplasm Metastasis
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00459654
- Testing
- Radium-223 dichloride (BAY88-8223), Saline
- Where
- 3 sites in Sweden, United Kingdom
- Volunteers
- 64 people
- Sponsor
- Bayer
Hormone Refractory Prostate Cancer
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
The purpose of this study is to determine the efficacy of patupilone chemotherapy and to find out what effects (good and bad) the drug Patupilone has on patients with prostate cancer that has progressed following hormone…
- Trial name
- NCT00407251
- Testing
- Patupilone
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer Patients Undergoing Radical Prostatectomy, Prostate CA
Research on PSMA-Targeted Intraoperative Fluorescent Imaging Agents
Phase I: Primary Research Objective: Evaluate the safety, tolerability, and pharmacokinetic characteristics of a single dose of DGPR1008 in healthy subjects.
- Trial name
- DGPR1008 (NCT07101354)
- Testing
- 0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6), 0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6), 0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Haitao Niu, MD
Prostate Cancer
Vaccine Treatment for Hormone Refractory Prostate Cancer
This 2-phase study will determine the safety of treating patients with prostate cancer with the genetically engineered HyperAcute-Prostate cancer vaccine.
- Trial name
- NCT00105053
- Testing
- HyperAcute-Prostate Cancer Vaccine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NewLink Genetics Corporation
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy.
- Trial name
- NCT03516812
- Testing
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Prostate Cancer
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status.
- Trial name
- NCT00545766
- Testing
- Vinflunine
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
Prostatic Neoplasm
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells.
- Trial name
- NCT00001266
- Testing
- Suramin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Men Undergoing Radical Prostatectomy
The purpose of this study is to see if the protein pattern in your blood can predict whether or not your prostate tumor is aggressive.
- Trial name
- NCT00582530
- Testing
- Whole Blood Draw
- Where
- United States
- Volunteers
- 513 people
- Sponsor
- Memorial Sloan Kettering Cancer Center